Janus Henderson Group PLC Raises Stake in Illumina, Inc. (NASDAQ:ILMN)

Janus Henderson Group PLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 40.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,168,057 shares of the life sciences company’s stock after purchasing an additional 625,245 shares during the period. Janus Henderson Group PLC’s holdings in Illumina were worth $282,735,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in ILMN. Industrial Alliance Investment Management Inc. purchased a new stake in shares of Illumina during the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV boosted its position in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Illumina during the 2nd quarter worth $61,000. Private Trust Co. NA boosted its position in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. Finally, Mizuho Securities Co. Ltd. purchased a new stake in shares of Illumina during the 2nd quarter worth $63,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Trading Down 3.1 %

NASDAQ ILMN opened at $140.60 on Wednesday. Illumina, Inc. has a 12 month low of $100.08 and a 12 month high of $156.66. The company has a 50-day moving average of $142.42 and a 200-day moving average of $126.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market cap of $22.30 billion, a P/E ratio of -14.12 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same quarter in the prior year, the company posted $0.33 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, equities analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on ILMN. StockNews.com began coverage on shares of Illumina in a research report on Thursday, August 29th. They issued a “buy” rating on the stock. Daiwa America upgraded shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Leerink Partners boosted their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Morgan Stanley reiterated an “equal weight” rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, November 12th. Finally, HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.